Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
/

LA JOLLA, Calif., July 15, 2019 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter ending May 31, 2019 and provided a corporate update.